Study S000017

Efficacy of Oral Semaglutide in Overweight or Obesity : Randomized Controlled Trial (OSO Study - Oral Semaglutide for Obesity)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05442450
Acronym: OSO
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: UNKNOWN
Enrollment: 116
Start: 2022-07-10
Primary completion: 2023-06-30
Lead sponsor: Asian Institute of Gastroenterology, India
Conditions: Obesity; Weight Loss
Interventions: DRUG:oral semaglutide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

The proportion of patients achieving a reduction in body weight of 5% or more from baseline [seven months]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016221	Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trial. Katrevula A, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology	2026	Randomized trial	PMID 41066034 DOI	cites ClinicalTrials.gov:NCT05442450; registry reference DERIVED:41066034